Corporate Governance

Board of Directors

The Board consults with staff, advisers, regulators, and other stakeholders when identifying key resources and relationships on which the business relies.

The Board is led by the Chairman and comprises nine members: six Directors and three Independent Directors. The selection and appointment of board members are based on business judgment, accounting and financial analysis, business management, crisis handling, industry knowledge, international market outlook, leadership, and decision-making capabilities. Each Board member has experience across multiple industrial fields. The skills and experience of each director are described on the website above.

The Chairman is responsible for leadership of the Board, ensuring its effectiveness in all aspects of its role, setting its agenda, and ensuring that the Directors receive accurate, timely, and clear information. The Chairman also ensures effective communication with shareholders and facilitates the effective contribution of the other Directors and Independent Directors. The shareholders have the ability to choose and appoint the Directors, and they can be re-elected. There shall be independent directors in the aforementioned number of directors, and the number of independent directors shall not be less than three and shall not be less than one-fifth of the number of directors.

The Company has listed its directors and independent directors on the website above.

For further information, please refer to Chapter IV: Directors in the Company’s Corporate Governance.

Directors

Andrew Lin, MS, MBA Chairman of the Board Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals.Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.Preceding his corporate executive roles, Andrew has served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio. Andrew was also the Head of Asia Pacific Technology Research for J.P. Morgan Securities and General Manager for J.P. Morgan Securities Taiwan.Before his sell-side and buy-side posts, Mr. Lin worked for management consulting firms, McKinsey & Company and Booz • Allen & Hamilton, in both Asia Pacific and the United States.Prior to his management consulting career, Mr. Lin worked for AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation in the United States in a research and development capacity.Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.

Andrew Lin, MS, MBA

Chairman of the Board

Andrew Lin is the Chairman of TaiRx, Inc. and Nuwa Healthcare. He also serves on the Independent Board of Directors for Fubon Insurance, and is the co-founder of Affinity Capitals.Before joining TaiRx, Andrew was Chairman of Lotus Pharmaceutical, the largest generic drug company listed on the Taiwan Stock Exchange, having previously been CEO of Hasumi Biotechnology International, a global leader in cancer vaccines and immunotherapy.Prior to his biotech career, Andrew’s most recent positions were Chief Strategy Officer for Chicony Electronics/Clevo Group, Managing Director with Macquarie Capital, and Chief Financial Officer for Lite-On Technology Group, a US$10 billion technology giant, headquartered in Taiwan.Preceding his corporate executive roles, Andrew has served as Chief Investment Officer for ABN AMRO Asset Management Taiwan, managing their US$4 billion investment portfolio. Andrew was also the Head of Asia Pacific Technology Research for J.P. Morgan Securities and General Manager for J.P. Morgan Securities Taiwan.Before his sell-side and buy-side posts, Mr. Lin worked for management consulting firms, McKinsey & Company and Booz • Allen & Hamilton, in both Asia Pacific and the United States.Prior to his management consulting career, Mr. Lin worked for AT&T Bell Laboratories, Prime Computer, and Digital Equipment Corporation in the United States in a research and development capacity.Andrew received his MBA degree from The University of Chicago, Graduate School of Business after graduating with an MS degree in electrical and computer engineering from the University of Massachusetts at Amherst.

Haishan Jang, PhD, MBA Vice Chairman, CGS (Chief Global Strategist) Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.

Haishan Jang, PhD, MBA

Vice Chairman, CGS (Chief Global Strategist)

Dr Haishan Jang has over 30 years of experience in the pharmaceutical industry. Prior to forming BRIM, she worked at Sterling Winthrop (Kodak), Sanofi, DuPont, and Centocor (J&J), where she was the Senior Director of Biologics Clinical Pharmacology. Haishan’s extensive experience across the entire drug discovery process, from research to clinical translation and commercial development, has given her the unique ability to understand the driving factors needed across all parts of a business to deliver world-class, life-changing innovation.Driven by her own need for continued learning, Haishan is passionate about developing and supporting young scientists in Taiwan – driving BRIM′s corporate mission to inspire and nurture the next generation of biotech entrepreneurs and innovators to bring sustainable and affordable healthcare to everyone.Haishan has a PhD in Physical Chemistry and an MBA from Temple University, Pennsylvania.

Audrey Tseng, MS, MBA Director Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang-Ming Chiao Tung University.Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies.Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.

Audrey Tseng, MS, MBA

Director

Audrey is an advisory member of the Bio Taiwan Committee (BTC), Vice Chairperson of the Taiwan Bio Industry organization, and an Adjunct Professor at National Yang-Ming Chiao Tung University.Audrey recently retired from serving as the Deputy Chairman of PwC Taiwan, Assurance Leader, and Bio-Industry Development Committee Leader. She has over 35 years of experience in accounting and sophisticated expertise in assisting biotech industry development and business strategies.Audrey holds an MBA from the Executive MBA Program of Fudan University and National Taiwan University, and a Master of Commerce from the Department of Accounting at National Chengchi University.

Isaiah Capital LLC Corporate Director Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.

Isaiah Capital LLC

Corporate Director

Isaiah Capital specializes in the investment and management of innovative technology industries. One of its representatives was the director of BRIM′s A round of fundraising and also invested in BRIM′s B and C rounds of fundraising. In the D round of fundraising, Isaiah Capital coordinated with BRIM to bring investors with more international capital market experience to help BRIM execute IPO strategies and establish international financial planning. Isaiah Capital also joined the most recent Series E round to continue to support BRIM′s growth.

CIDC Consultants Corporate Director Established in 1988, Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses in the hope to do its part and contribute to the growth of domestic venture capital and high-tech industries.Over the years, CIDC Consultants has invested over NT$18 billion in 330 domestic and foreign companies and successfully exited a third of them with over NT$ 6 billion of profits. Members of its investment team have served on the board of directors or board of supervisors of 65 portfolio companies and helped their growth to create an outstanding record in capital management.

CIDC Consultants

Corporate Director

Established in 1988, Li-teh Hsu, the chairman of China Investment & Development (CIDC), brought together funding, professional expertise, and human resources from large companies in both Taiwan and Canada to implement investment plans benefiting both investors and the broader economy in Taiwan. He established China Investment & Development Company, Limited with a capital of NT$1.6 billion and a mission encompassing production, trade, services, and investment in technology businesses in the hope to do its part and contribute to the growth of domestic venture capital and high-tech industries.Over the years, CIDC Consultants has invested over NT$18 billion in 330 domestic and foreign companies and successfully exited a third of them with over NT$ 6 billion of profits. Members of its investment team have served on the board of directors or board of supervisors of 65 portfolio companies and helped their growth to create an outstanding record in capital management.

Affinity Limited Partnership Fund One Corporate Director Affinity Limited Partnership Fund One focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive expertise in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.

Affinity Limited Partnership Fund One

Corporate Director

Affinity Limited Partnership Fund One focuses on investing in Taiwan’s life science and health industries. The members of the management team are all senior experts with extensive expertise in life sciences, capital markets, investment, mergers and acquisitions, and post-investment management, as well as profound capabilities in business operations.

Independent Directors

James Cheng, JD Independent Director Mr. James Cheng is a partner with Tsar & Tsai Law Firm. James is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement.On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects.James has previously successfully represented a government project bidder in administrative litigation against a government agency relating to another bidder′s status as the best bidder for the BOT project for a highway electronic toll collection system and obtained the first-ever winning judgment to revoke the other bidder′s best bidder status.On the transaction side, James is involved in numerous high-profile cross-border mergers and acquisitions by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure. James has successfully represented private equity funds in the acquisition of cable multiple system operators in Taiwan, a restaurant chain in the sale of business operations in Taiwan and Beijing, a conglomerate in the purchase of a television channel business, and a high-tech company in the acquisition of a company abroad.As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.

James Cheng, JD

Independent Director

Mr. James Cheng is a partner with Tsar & Tsai Law Firm. James is both a litigator and a transaction attorney. His areas of specialty include corporate law, insurance, M&A, capital markets, cross-border transactions, BOT projects, and government procurement.On the litigation side, James has assisted numerous high-tech companies on intellectual property disputes, directors of various companies on allegations of breach of trust and breach of fiduciary duty, contractors and construction consulting firms on construction defect cases, and companies having disputes relating to government projects.James has previously successfully represented a government project bidder in administrative litigation against a government agency relating to another bidder′s status as the best bidder for the BOT project for a highway electronic toll collection system and obtained the first-ever winning judgment to revoke the other bidder′s best bidder status.On the transaction side, James is involved in numerous high-profile cross-border mergers and acquisitions by assisting the client in deal structure, contract negotiation, syndication loan documentation, and post-closing restructure. James has successfully represented private equity funds in the acquisition of cable multiple system operators in Taiwan, a restaurant chain in the sale of business operations in Taiwan and Beijing, a conglomerate in the purchase of a television channel business, and a high-tech company in the acquisition of a company abroad.As an insurance law expert, James also represents multiple insurance businesses in Taiwan on insurance business regulatory compliance matters and claim disputes.

Howard Kuo, MBA Independent Director Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning.Howard holds an MBA from the Executive MBA Program of National Taiwan University.

Howard Kuo, MBA

Independent Director

Mr Howard Kuo currently serves on the board of directors in many public and private companies in Taiwan. After retiring from his role as Deputy Chairman of PwC Taiwan and as a lead accountant for Family Business Inheritance and Personal Assets and Tax Management, he continued to teach in the universities and provide guidance to startups. He has over 35 years of experience in accounting and extensive expertise in tax affairs and corporate cross-border investment structure and planning.Howard holds an MBA from the Executive MBA Program of National Taiwan University.

Johnsee Lee, PhD, MBA Independent Director Dr. Johnsee Lee is the founder, President, and CEO of Personal Genomics, Inc., and has held various technical and managerial positions at Argonne National Laboratories, Johnson Matthey Inc., and Industrial Technology Research Institute (ITRI).Johnsee has many years of hands-on experience in both frontier technology research and industrial commercialization. He received a Ph.D. from the Illinois Institute of Technology and an MBA from the University of Chicago and is a graduate of Harvard Business School’s Advanced Management Program.After joining ITRI, Johnsee worked his way up from a lab manager to become President of the Institute and played a key leadership role in the development of Taiwan′s world-class high-tech industry. He was the first Director and founder of the Biomedical Engineering Center at ITRI, with expertise covering chemical, biochemical, and molecular technologies.Johnsee is specialized in multidisciplinary technology integration and has successfully led the exploratory research team to develop and commercialize novel technologies for healthcare applications. During his tenure as the President of ITRI, he has created 16 high-tech start-ups and actively supported them with the institute’s incubation and venture programs.Johnsee has published many journal papers and patents. He is also a recipient of the National Engineering Medal, Economics Contribution Award, and Innovation Leadership Award by Global Views Magazine.He is an Adjunct Professor at Taipei Medical University, Chairman of the Development Center for Biotechnology in Taiwan, and Director of the Board of Taiwan Semiconductor Manufacturing Co. (TSMC). 

Johnsee Lee, PhD, MBA

Independent Director

Dr. Johnsee Lee is the founder, President, and CEO of Personal Genomics, Inc., and has held various technical and managerial positions at Argonne National Laboratories, Johnson Matthey Inc., and Industrial Technology Research Institute (ITRI).Johnsee has many years of hands-on experience in both frontier technology research and industrial commercialization. He received a Ph.D. from the Illinois Institute of Technology and an MBA from the University of Chicago and is a graduate of Harvard Business School’s Advanced Management Program.After joining ITRI, Johnsee worked his way up from a lab manager to become President of the Institute and played a key leadership role in the development of Taiwan′s world-class high-tech industry. He was the first Director and founder of the Biomedical Engineering Center at ITRI, with expertise covering chemical, biochemical, and molecular technologies.Johnsee is specialized in multidisciplinary technology integration and has successfully led the exploratory research team to develop and commercialize novel technologies for healthcare applications. During his tenure as the President of ITRI, he has created 16 high-tech start-ups and actively supported them with the institute’s incubation and venture programs.Johnsee has published many journal papers and patents. He is also a recipient of the National Engineering Medal, Economics Contribution Award, and Innovation Leadership Award by Global Views Magazine.He is an Adjunct Professor at Taipei Medical University, Chairman of the Development Center for Biotechnology in Taiwan, and Director of the Board of Taiwan Semiconductor Manufacturing Co. (TSMC).